Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Bhojwani

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Blood|September 5, 2008
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemiaJun J Yang, Deepa Bhojwani, Wenjian Yang, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Pediatric Blood & Cancer|June 21, 2022
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortiumEric S Schafer, Karen Chao, Alexandra M Stevens, et al.
Leukemia|February 20, 2020
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacyG A Amos Burke, Auke Beishuizen, Deepa Bhojwani, et al.
Blood Cancer Discovery|December 3, 2024
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T CellsSamy Jambon, Jianping Sun, Shawn Barman, et al.
Cancer|February 7, 2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemiaSima Jeha, Elaine Coustan-Smith, Deqing Pei, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Blood Advances|December 21, 2022
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trialG A Amos Burke, Luciana Vinti, Edita Kabickova, et al.
The Lancet. Oncology|March 25, 2015
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective studyChing-Hon Pui, Deqing Pei, Elaine Coustan-Smith, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Blood|September 5, 2008
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemiaJun J Yang, Deepa Bhojwani, Wenjian Yang, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Pediatric Blood & Cancer|June 21, 2022
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortiumEric S Schafer, Karen Chao, Alexandra M Stevens, et al.
Leukemia|February 20, 2020
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacyG A Amos Burke, Auke Beishuizen, Deepa Bhojwani, et al.
Blood Cancer Discovery|December 3, 2024
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T CellsSamy Jambon, Jianping Sun, Shawn Barman, et al.
Cancer|February 7, 2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemiaSima Jeha, Elaine Coustan-Smith, Deqing Pei, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Blood Advances|December 21, 2022
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trialG A Amos Burke, Luciana Vinti, Edita Kabickova, et al.
The Lancet. Oncology|March 25, 2015
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective studyChing-Hon Pui, Deqing Pei, Elaine Coustan-Smith, et al.
Pageof 13